X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
AMAR REMEDIES Quarterly Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AMAR REMEDIES Quarterly Results   (AMAD)

Here are the latest quarterly results of AMAR REMEDIES. For more details, see the AMAR REMEDIES financial fact sheet and AMAR REMEDIES share price and chart. For a sector overview, read our pharmaceuticals sector report.

Excel Export | Annual Financial Info | Result Scoreboard

AMAR REMEDIES Quarterly Results

No. of Mths
Qtr. Ending
3
Sep-11
3
Dec-11
3
Mar-12
3
Jun-12
3
Sep-12
3
Dec-12
3
Mar-13
3
Jun-13
8-Qtr Chart
Click to enlarge
Net Sales Rs m1,5911,6491,6931,8111,5241,6301,310452 
Other income Rs m014525420 
Turnover Rs m1,5911,6631,6981,8131,5291,6341,312452 
Expenses Rs m1,3591,4051,4131,4371,3631,4471,219531 
Gross profit Rs m23224427937316018391-80 
Depreciation Rs m2828284331474721 
Interest Rs m8890104116119124139146 
Profit before tax Rs m1161401522161516-93-247 
Tax Rs m181823643300 
Profit after tax Rs m981221291521213-93-247 
Gross profit margin %14.614.816.520.610.511.26.9-17.7 
Effective tax rate %15.512.915.129.620.018.80.00.0 
Net profit margin %6.27.47.68.40.80.8-7.1-54.6 
Diluted EPS Rs 3.7 4.7 4.9 5.8 0.5 0.5 -3.6 -9.4  
Diluted EPS (TTM) Rs 15.0 16.1 17.3 19.2 15.9 11.7 3.2 -12.0  
 Subscriber Feature                  
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Annual Reports, Regulatory Filings, Equitymaster

More Consumer Products Company Quarterly Results:   ASTRAZENECA PHARMA  ALEMBIC LTD  SUN PHARMA  DISHMAN PHARMA  AJANTA PHARMA  

Compare AMAR REMEDIES With:   ASTRAZENECA PHARMA  ALEMBIC LTD  SUN PHARMA  DISHMAN PHARMA  AJANTA PHARMA  

Compare AMAR REMEDIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Views on news

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AMAR REMEDIES SHARE PRICE


Dec 11, 2013 (Close)

TRACK AMAR REMEDIES

  • Track your investment in AMAR REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AMAR REMEDIES

AMAR REMEDIES 5-YR ANALYSIS

COMPARE AMAR REMEDIES WITH

MARKET STATS